Source comparison
PT-141 Studied Appetite Control Research: Dosing and Receptor Selectivity Comparison
PT-141 (Bremelanotide) MC3R, MC4R (non-selective) 2–3 hours 22–31% caloric reduction in rodent models at 1–3mg/kg Hypoactive sexual desire disorder (HSDD) Single-use before sexual activity Setmelanotide MC4R (selective) 11 hours Phase III trial: 25.6% mean bod
This comparison does not assign a generated winner or score.
- PT-141 (Bremelanotide)
- MC3R, MC4R (non-selective)
- 2–3 hours
- 22–31% caloric reduction in rodent models at 1–3mg/kg
- Hypoactive sexual desire disorder (HSDD)
- Single-use before sexual activity
- Setmelanotide
- MC4R (selective)
- 11 hours
- Phase III trial: 25.6% mean body weight reduction at 52 weeks
- POMC/LEPR deficiency obesity
- Once-daily subcutaneous injection
- Alpha-MSH (endogenous)
- MC1R, MC3R, MC4R, MC5R
- <10 minutes
- Transient appetite suppression in animal models
- None (endogenous ligand)
- N/A. Endogenous release
- Semaglutide (GLP-1 agonist)
- GLP-1 receptor
- 7 days
- 14.9% mean body weight reduction (STEP-1 trial)
- Type 2 diabetes, obesity
- Once-weekly subcutaneous injection
- The table underscores a critical gap: PT-141's receptor activation profile is nearly identical to setmelanotide's, but its short half-life prevents the sustained exposure required for meaningful weight loss. Researchers studying melanocortin pathways use PT-141 as a pharmacological tool to probe MC4R function in acute experimental settings. Not as a weight management candidate.